Immune tolerance and immunosuppression in solid organ transplantation.
S Afr Med J
; 104(11): 7307, 2014 Oct 06.
Article
in En
| MEDLINE
| ID: mdl-29183441
ABSTRACT
Organ transplantation is the treatment of choice for patients with end-stage organ failure. Most of them will require lifelong immunosuppression to prevent both acute and chronic rejection. T-cell recognition of the allograft major histocompatibility complex antigens is the central event initiating cellular rejection of the allograft, and subsequent full T-cell activation requires three signals.Immunosuppressive regimens currently used in clinical practice are nonspecific and target T-cell activation, clonal expansion or differentiation into effector T cells. While these therapeutic regimens have advanced considerably and one-year graft survival figures for most solid organ transplants (SOTs) are >90%, the long-term graft survival remains fair owing to graft loss from chronic rejection. The 'holy grail' of SOT is therefore the development of a permanent specific immune tolerance against donor allogeneic antigens without the long-term use of immunosuppression.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
S Afr Med J
Year:
2014
Document type:
Article
Affiliation country:
Sudáfrica
Publication country:
SOUTH AFRICA
/
SUDAFRICA
/
ZA
/
ÁFRICA DO SUL